Clinical trials have shown that semaglutide and liraglutide are generally well tolerated, with gastrointestinal disorders being the most commonly reported AEs, including nausea, diarrhea, vomiting, and constipation, leading to dose reduction or temporary treatment interruption in 12.5% of study participants [40,41,42]
These details will help CPGs create the foods this growing population wants as they look for foods to fit their new tastes and preferences
AstraZeneca plc Biolingus Boehringer Ingelheim GmbH D&D Pharmatech Daiichi Sankyo Company, Limited Eli Lilly and Company Gmax Biopharm Hanmi Pharmaceutical Co., Ltd
Weight Loss Benefits GLP-1s suppress appetite, often leading to 1020% body weight loss in clinical trials
But for cyclists seeking a performance edge through weight loss, they're a complex and potentially risky proposition
N Engl J Med 2019;380:347-57